Suzuken posts higher sales but weaker profits and lower equity ratio for nine months

Suzuken Co ( (JP:9987) ) has issued an announcement.

Suzuken reported consolidated net sales of ¥1.89 trillion for the nine months to December 31, 2025, up 2.6% year on year, while operating and ordinary profits declined 8.6% and 5.2%, respectively. Profit attributable to owners of parent inched up 1.1% to ¥31.0 billion, with basic earnings per share rising to ¥439.74, aided by a lower average share count following share repurchases.

Total assets expanded sharply to ¥1.31 trillion from ¥1.11 trillion at the previous fiscal year-end, but the equity ratio fell to 31.0% from 36.6%, indicating higher leverage or liabilities on the balance sheet. The company kept its dividend policy unchanged, maintaining an annual forecast of ¥100 per share, and reiterated its full-year guidance, projecting modest 2.8% sales growth but mid‑ to high‑single‑digit declines in profits, suggesting margin pressure despite revenue expansion.

The most recent analyst rating on (JP:9987) stock is a Hold with a Yen7029.00 price target. To see the full list of analyst forecasts on Suzuken Co stock, see the JP:9987 Stock Forecast page.

More about Suzuken Co

Suzuken Co., Ltd. is a Japan-based healthcare company listed on the Tokyo, Nagoya and Sapporo exchanges, operating primarily in the pharmaceutical wholesale and related medical distribution sector. The group focuses on supplying prescription drugs and healthcare products nationwide, positioning itself as a key intermediary in Japan’s medical and pharmaceutical supply chain.

Average Trading Volume: 166,845

Technical Sentiment Signal: Buy

Current Market Cap: Yen371.8B

Learn more about 9987 stock on TipRanks’ Stock Analysis page.